Modality
Peptide
MOA
MALT1i
Target
Cl18.2
Pathway
JAK/STAT
RCCGBM
Development Pipeline
Preclinical
~Sep 2021
→ ~Dec 2022
Phase 1
~Mar 2023
→ ~Jun 2024
Phase 2
Sep 2024
→ Feb 2028
Phase 2Current
NCT08786407
984 pts·GBM
2025-07→2026-03·Completed
NCT04621678
12 pts·GBM
2024-09→2028-02·Not yet recruiting
996 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-073w agoPh3 Readout· GBM
2026-05-262mo awayEnrollment Complete· RCC
2028-02-221.9y awayPh3 Readout· GBM
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Not yet…
P2/3
Complet…
Catalysts
Ph3 Readout
2026-03-07 · 3w ago
GBM
Enrollment Complete
2026-05-26 · 2mo away
RCC
Ph3 Readout
2028-02-22 · 1.9y away
GBM
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08786407 | Phase 2/3 | GBM | Completed | 984 | EDSS |
| NCT04621678 | Phase 2/3 | GBM | Not yet recr... | 12 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |